Several studies have demonstrated that BEZ235, a dual PI3K and mTOR inhibitor, enhanced radiosensitivity in glioblastoma cells, laryngeal cancer cells, and hypopharyngeal cancer cells through the inhibition of ATM and DNA-PKcs-associated DNA repair [25,26,27]. This evidence concerns the gene PRKDC and glioblastoma.